Bring on the generics, so long blockbusters! Zyprexa,Seroquel,Lexapro,Geodon & more about to drop off the patent cliff

VIA PharmaGossip

These are blockbuster drugs, with more than $1 billion in annual global sales,
set to go off patent and get generic competition in the U.S. in the next two
years:

Oct. 2011 Zyprexa olanzapine schizophrenia/bipolar Eli
Lilly

Nov. 2011 Lipitor atorvastatin high cholesterol Pfizer

March 2012 Lexapro escitalopram depression Forest
Labs

March 2012 Seroquel quetiapine schizophrenia/bipolar
AstraZeneca

March 2012 Avapro/Avalide irbesartan high blood pressure

Bristol-Myers/Sanofi

April 2012 Provigil modafinil narcolepsy Cephalon

May 2012 Plavix clopidogrel clot prevention

Bristol-Myers/Sanofi

July 2012 Tricor fenofibrate high triglycerides Abbott

Aug. 2012 Singulair montelukast asthma/allergies Merck

Aug. 2012 Actos pioglitazone diabetes Takeda

Sept. 2012 Diovan valsartan high blood pressure Novartis

Sept. 2012 Geodon ziprasidone bipolar disorder Pfizer

Nov. 2012 Lidoderm lidocaine pain patch Endo

Dec. 2012 Atacand candesartan heart failure

AstraZenecaMarch 2013 Lovaza omega-3-acid high triglycerides
GlaxoSmithKlineAug. 2013 Temodar temozolomide brain tumors Merck
------
Note: Patent expiration/generic arrival dates can change due to litigation orregulatory issues.

Sources: Medco Health Solutions Inc., company Web sites.

via finance.yahoo.com